Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hemophilia
Biotech
Centessa drops hemophilia B drug following Pfizer’s Hympavzi win
After Pfizer secured approval for Hympavzi, Centessa decided that taking its own contender to market isn't worth the effort.
James Waldron
Nov 12, 2024 9:45am
Pfizer gene therapy reduces bleeds in ph. 3 hemophilia A trial
Jul 24, 2024 8:44am
Novo unwraps phase 3 data on rival to Roche in hemophilia A
Jun 24, 2024 5:26am
Novo Nordisk's Hemlibra rival hits goals in phase 3
May 14, 2024 9:16am
ASH: Pfizer swims in crowded sickle cell, hemophilia waters
Dec 9, 2023 7:00pm
BioMarin looks to up pace of new drug filings
Sep 12, 2023 3:58pm
